For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than standard therapy alone, according to a study published online Feb. 7 in the New England Journal of Medicine. The research was published to coincide with the International Society of Nephrology annual World Congress of Nephrology, held from Feb. 6 to 9 in New Delhi.
Leave A Comment